Evidence map›Paper›PMID 19262145›Full record

ReviewCell adhesion & migration

Amoeboid chemotaxis: future challenges and opportunities.

Tatiana Smirnova, Jeffrey E Segall

Open access · bronzeAbstract readReview
In one paragraph

Review in Cell adhesion & migration. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 3 papers.

0numbers the graph read from it
0cells of the map it votes in
3citing papers in PubMed
0.4field-weighted citation impact, top 41% of its field
1 · What the graph read from it

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

2 · The registry

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.

3 · Its place in the literature

Who cites it

3 citing papers in PubMed, 8 citations in OpenAlex.

  1. Article
  2. Article
  3. In vivo assay for tumor cell invasion.Methods in molecular biology (Clifton, N.J.) · 2009
    Article
4 · The record

Corrections and comments

PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.

5 · Who and what money

Authors and funding

2 authors at 1 institution in 1 country.

Tatiana SmirnovaDepartment of Anatomy and Structural Biology, Albert Einstein College of Medicine, Bronx, New York 10461 , USA.
Jeffrey E Segall
Albert Einstein College of Medicine · US

Funding

Tumor Progression and MetastasisP01CA100324 · NCI · YESHIVA UNIVERSITY · PI CONDEELIS, JOHN S · 2003 to 2018
$30.0M
ERBB1 AND ERBB2 IN TUMOR MOTILITY AND METASTASISR01CA077522 · NCI · YESHIVA UNIVERSITY · PI SEGALL, JEFFREY E · 2000 to 2011
$3.0M
NCI NIH HHS CA100324NCI NIH HHS CA77522NCI NIH HHS P01 CA100324NCI NIH HHS R01 CA077522
6 · The paper itself

Abstract

Chemotaxis is the directed movement of a cell towards a gradient of chemicals such as chemokines or growth factors. This phenomenon can be studied in organisms ranging from bacteria to mammalian cells, and here we will focus on eukaryotic amoeboid chemotaxis. Chemotactic responses are mediated by two major classes of receptors: GPCR's and RTK's, with multiple pathways signaling downstream of them, certain ones functioning in parallel. In this review we address two important features of amoeboid chemotaxis that will be important for further advances in the field. First, the application of in vivo imaging will be critical for providing insight into the functional requirements for chemotactic responses. We will briefly cover a number of systems in which in vivo imaging is providing new insights. Second, due to the network-type design of signaling pathways of eukaryotic chemotaxis, more refined phenotypic analysis will be necessary, and we will discuss recent analyses of the role of the phosphoinositide 3-kinase pathway in this light. We will close with some speculations regarding future applications of more detailed in vivo analysis and mechanistic understanding of eukaryotic amoeboid chemotaxis.

Indexed as

AnimalsChemotaxisHumansPhosphatidylinositol 3-KinasesReceptors, G-Protein-CoupledSignal TransductionTachykininsPhosphatidylinositol 3-KinasesReceptors, G-Protein-CoupledTachykinins

Identifiers

PMID19262145
PMCPMC2634101
OpenAlexW1974337533

What OpenQuestion holds

Textmetadata
Read underepoch 390

Registered trials

None linked

Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.